Should Helicobacter pylori infection be treated prior to long-term proton pump inhibitor therapy?

Medicina Clinica

Volumn 117, Issue 20, 2001, Pages 793-797

  Gisbert, Javier P ^a   Pajares, José María ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Atrophy; Eradication; Esophagitis; Gastric cancer; Helicobacter pylori; Intestinal metaplasia; Omeprazole; Proton pump inhibitors; Treatment

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; PROTON PUMP;

ATROPHIC GASTRITIS; CELL PROLIFERATION; EPITHELIUM CELL; ERADICATION THERAPY; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; MEDICAL LITERATURE; REVIEW; CONSENSUS DEVELOPMENT; DRUG ANTAGONISM; TIME;

CONSENSUS DEVELOPMENT CONFERENCES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMPS; TIME FACTORS;

EID: 0035894663     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)72261-0     Document Type: Review

References (80)

1. Conferencia Española de Consenso sobre la infección por Helicobacter pylori
2. Long-term treatment with omeprazol for refractory reflux exophagitis: Efficacy and safety
3. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment
4. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
5. Results of renal replacement therapy in Europe, 1980 to 1987. Registration Committee of the EDTA-ERA
6. Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: A randomized double-blind, placebo-controlled study
7. Changes in Helicobacter pylory-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease
8. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls
9. Changes in Helicobacter pylori induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-esophageal reflux disease
10. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-term safety
11. Review article: The development of atrophic gastritis - Helicobacter pylori and the effects of acid suppressive therapy
12. 12 levels
13. Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics
14. Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence
15. Omepazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety
16. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication
17. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole
18. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor of argyrophil cell hyperplasia
19. Antisecretory drugs increase corpus gastritis but only in the presence of Helicobacter pylori infection
20. Long-term acid suppressive therapy with half-dose of H2-receptor antagonist does not lead to a strong increase in corpus gastritis
21. Long-term omeprazole treatment in resistant gastroesophageal reflux: Efficacy, safety, and influence on gastric mucosa
22. Omeprazole, Helicobacter pylori status, and alterations in the intragastric millieu facilitating bacterial N-nitrosation
23. Gastric cancer risk in chronic athropic gastritis: Statistical calculations of cross-sectional data
24. Chaning patterns of Helicobacter pylori gastritis in lon-standing acid suppression
25. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy
26. Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole
27. Eradicatting Helicobacter pylori reduces hypegastrinaemia during long-term omeprazole treatment
28. Stimulation of growth of a colon cancer cell line by gastrin
29. The effect of gastrin on growth of human stomach cancer cells
30. Acid suppression and gastric atrophy: Sifting fact from fiction
31. Atrophy, acid suppression and Helicobacter pylori infection: A tale of two studies
32. Proton pump inhibidors do not accelerate the development of gastric atrophy in Helicobacter gastritis
33. Lack of effect of acid suppression therapy on gastric atrophy
34. Long-term proton pump inhibitor therapy accelerates the onset of atrophic gastritis in Helicobacter pylori-positive patients
35. A model for gastric cancer epidemiology
36. Are there three types of Helicobacter pylori gastritis?
37. Evolution of antral gastritis under chronic proton pump inhibitor therapy
38. Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management
39. Helicobacter pylori and gastroesophageal reflux disease: Friends or foes
40. Should we eradicate. Helicobacter pylori in patients with recurrent gastroesophageal reflux disease?
41. Review article: Is Helicobacter pylori status relevant in the management of GORD?
42. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis
43. Long-term consequences of Helicobacter pytlori eradication: Clinical aspects
44. Helicobacter pylori in gastro-oesophageal reflux disease: Causal agent, independent or protective factor?
45. Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: An unexplored triangle
46. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: Impacts of hiatal hernia and corpus gastritis
47. Helicobacter pylori eradication associated with gastroesophageal reflux disease?
48. Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis
49. Reflux esophagitis in duodenal ulcer patients
50. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia
51. Obesity and gastro-oesophageal reflux: Is there a relationship?
52. Are gastroesophaeal reflux disease in patients with duodenal ulcer?
53. Twenty-four hour esophageal pH-metry in patients with non-ulcer dyspepsia is unchanged after H. pylori eradication
54. The effect of Helicobacter pylori eradication on gastroeoesophageal reflux
55. The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population
56. Recurrent symptoms and gastro-esophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection
57. Symptomatic benefit 1-3 years after. H. pylori eradication in ulcer patients: Impact of gastroesophageal reflux disease
58. Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent?
59. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole
60. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
61. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole
62. Intragastric pH during treatment with omeprazole: Role of Helicobacter pylori and H. pylori-associated gastritis
63. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients
64. Gastritis, Helicobacter pylori, and proton pump inhibitors
65. Review article: The clinical influence of Helicobacter pylori in effective acid suppression-implications for the treatment of gastrooesophageal reflux disease
66. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects
67. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole
68. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease
69. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole
70. The influence of Helicobacter pylori on opesophageal acid exposure in GERD during suppressive therapy
71. Fundic gland polyps developing during omeparazole therapy
72. Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective
73. Helicobacter pylori and gastric diseases
74. Guidelines for the management of Helicobacter pylori infection
75. Canadian Helicobacter pylori consensus conference
76. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection
77. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastro-enterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE)
78. For what conditions is there evidence justification for treatment of Helicobacter pylori infection?
79. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors
80. Current European concepts in the management of Helicobacter pylori infection - The Maastricht Consensus Report